Tonix Pharmaceuticals Holding Corp. (TNXP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tonix Pharmaceuticals Holding Corp. on September 30, 2025. The report discloses specific corporate events and pricing announcements rather than periodic financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial data disclosed relates to product pricing:
- Tonmya Wholesale Acquisition Cost (WAC): $1,860 per month for a 60-count supply for the treatment of fibromyalgia in adults.
- Geriatric/Mild Hepatic Impairment WAC: $930 per month for a 30-count supply.
Material Changes
The filing reports two primary events effective September 29, 2025:
- Executive Appointment: Ganesh Kamath was appointed as Head of Market Access.
- Pricing Announcement: The Company established the WAC for its product Tonmya.
Guidance, Outlook, and Risks
The document contains forward-looking statements regarding product development, clinical trials, regulatory timelines, and market opportunity. Management cautions that actual results may differ materially due to known and unknown risks. The Company explicitly states it undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the commercial launch status and distribution agreements for Tonmya following the WAC announcement.
- Confirm the background and prior experience of Ganesh Kamath in the pharmaceutical market access sector.
- Review the Company's most recent 10-Q or 10-K for actual financial performance, as this 8-K contains no operational financial data.
- Assess the competitive landscape for fibromyalgia treatments to evaluate the market viability of the $1,860/month price point.